1. Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay
   Audrey Vallée et al, 2019, PLOS ONE CrossRef
2. BRAF mutations might be more common than supposed in vulvar melanomas
   Sophie Wylomanski et al, 2018, Experimental Dermatology CrossRef
3. Efficient treatment of a metastatic melanoma patient with a combination of BRAF and MEK inhibitors based on circulating tumor DNA analysis: a case report
   Gaelle Quéreux et al, 2017, BMC Research Notes CrossRef
4. Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic BRAF or NRAS-Mutated Melanoma Patients
   Guillaume Herbreteau et al, 2020, Cancers CrossRef
5. BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis
   L. Ny et al, 2020, Acta Oncologica CrossRef
6. Clinical significance of BRAF mutation status in circulating tumor DNA of metastatic melanoma patients at baseline
   Anne C. Knol et al, 2016, Experimental Dermatology CrossRef